Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (1115)	3/23/2000 9:38:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

Ron et al: The April edition of Scientific American has an excellent article on "Understanding Clinical Trials". It is worth reading for those who don't have much experience in this area. One point made involves the goal of Phase 2 as follows "The main goal of phase II testing is pragmatic: to find the experimental conditions that will allow the final phase of the trial to give a definitive result. (The purpose of a phase II trial is not, as some people assume, to prove that a drug candidate is an effective treatment)". This goal is what Pars achieved as stated in their release. To my mind, the real question is what kind of an end point the FDA will be comfortable with. Presumably, the company is seeking to answer that. Cheers, Arnie